Podcasts about Lung cancer

Dr. Trudy G. Oliver is a Professor in the Department of Pharmacology & Cancer Biology as well as a Duke Science and Technology Scholar at Duke University. Trudy's research focuses on small cell lung cancer, a disease known for its remarkable ability to "shape-shift" or undergo cellular plasticity. This adaptability allows cancer cells to change types and develop different therapeutic vulnerabilities (or invulnerabilities), making treatment especially challenging and preventing the development of a one-size-fits-all approach. When she's not in the lab, Trudy unwinds with walks, jogs, music, and true-crime podcasts. She also enjoys spending quality time with friends, family, and her two energetic orange kittens named Basal and Tuft after her favorite lung cell types. She received her Bachelor's degree in chemistry from Oklahoma Baptist University, and her PhD in cancer biology from Duke University. Afterwards, she conducted postdoctoral research at the University of North Carolina, Chapel Hill, and subsequently at MIT. Trudy served on the faculty at the University of Utah for more than a decade before joining the faculty at Duke University where she is today. She has received numerous awards and honors for her work, including the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer from the IASLC World Lung Conference, the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation, the Lung Cancer Discovery Award from the American Lung Association, the American Cancer Society Research Scholar Award, the Damon Runyon-Rachleff Innovation Award, and the Jimmy V Scholar Award from the V Foundation for Cancer Research. In this interview, Trudy shares more about her life and science.

How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient's treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS The panel, featuring specialists from various institutions, discusses the specifics of sequencing therapies, the impact of targeted and immunotherapies, and the nuances of treating different patient profiles, including non-smokers and those with specific genetic mutations. The conversation also touches on the integration of new staging systems, the benefits of multidisciplinary clinics, and the ongoing evolution of cancer treatment trials. The discussion aims to provide clarity on the latest advancements and future directions in managing lung cancer, emphasizing the importance of tailored treatment plans and the potential of emerging technologies. --- TIMESTAMPS 00:00 - Introduction05:16 - Molecular Diagnostics and Liquid Biopsy21:43 - Targeted Therapy Options27:29 - Managing Toxicities and Treatment Strategies33:13 - Challenges with Immunotherapy in Special Cases34:07 - Lung Transplantation in Cancer Patients48:38 - Multidisciplinary Clinics and Collaboration01:06:29 - Future Directions --- RESOURCES ADAURA Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2027071 Gomez NSCLChttps://pmc.ncbi.nlm.nih.gov/articles/PMC5143183/

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC. Guest: Li Zhang, MD Professor, Medical Oncology Department Sun Yat-Sen University Cancer Center No Social Guest: Elaine Shum, MD Assistant Professor Director of Cancer Screening Programs New York University Perlmutter Cancer Center

Lung cancer is the most prevalent cancer in the Rochester and Finger Lakes region. That's according to experts at the University of Rochester Medical Center. They say screening has been underutilized due to the stigma of the disease. This hour, we discuss their efforts to change that. They also explain what they call a "soup to nuts" approach to addressing the disease, which includes prevention and screening, early diagnosis, and advanced treatment options. Our guests: Racquel Stephen, health, equity and community reporter and producer for WXXI News Charles Kamen, Ph.D., M.P.H., associate director of community outreach and engagement at Wilmot Cancer Institute at the University of Rochester Medical Center M. Patricia Rivera, M.D., C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine and chief of the Pulmonary and Critical Care Medicine Division at University of Rochester Medical Center Joyce Lucas, patient ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

his episode of 'Conversations in Lung Cancer Research' hosted by Dr Alex Davis, features a discussion with Dr. Laird Cameron and Dr. Annie Wong on the current state of lung cancer care and research in New Zealand. The panel explores the challenges and disparities faced by thoracic cancer patients, particularly among the indigenous Māori population. The conversation highlights the differences between patient populations in New Zealand and Australia, the impact of rurality on cancer care, the importance of clinical trials and multinational collaborations, and the future prospects for lung cancer treatments and interventions. (00:00) Introduction and Acknowledgements(01:01) Exploring Lung Cancer in New Zealand(01:13) Meet the Experts: Dr. Laird Cameron and Dr. Annie Wong(01:48) Challenges in Lung Cancer Diagnosis and Treatment(02:44) Specialisation Stories: Why Lung Cancer?(05:20) Comparing Patient Populations: New Zealand vs. Australia(07:44) Lung Cancer Care Pathways in New Zealand(09:17) Access to Treatments and Therapies(14:57) The Role of Lung Cancer Nurses(18:21) Rural Challenges in Lung Cancer Care(22:06) Radiology and Diagnostic Delays(23:08) CTDNA and Liquid Biopsy in New Zealand(25:03) Strengths and Weaknesses in Lung Cancer Care(29:29) The Impact of Clinical Trials and TOGA(33:00) Future Interventions and Wishlists(39:33) Concluding Thoughts and Farewell

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses a lung cancer study that was conducted by Northwestern Medicine and who should be screened.

If you are sick or know someone who is, this podcast will build and strengthen your faith as you believe God for a healing miracle. 13 years ago God dramatically healed me of lung cancer, and He can do the same for you when you believe and stand on His promises! God is not a man that He should lie, nor will He change His mind, what He has said that will He do (Numbers 23:19). You can be certain of this one thing, God answers prayer! Jesus said 'lay your hands on the sick and they shall recover'. If you are in need of healing put your hand where the sickness is and say this prayer in faith and with conviction. - Then do what you could not do! I know Jesus is alive! I believe the Bible: God cannot lie! Your Word says Jesus took my sickness and healed me - so by faith I take my healing. In Jesus' Name I will fight in prayer and in the Word of God until I am healed! I command you devil, get out of my body! My body is a Temple of the Holy Spirit. Devil, get out of my life, my home, my family! In Jesus' Name I defeat you! I will not die, but live, and declare the works of the Lord! And I will live in health and victory until Jesus comes! Amen! Listen to my testimony, and be inspired by the beautiful worship of Vinesong, as together we declare God's healing power over your life. 'God answers prayer' and 'Run to the Father' used by kind permission of Vinesong

Asthma and COPD may be the ‘bread and butter' of the respiratory conditions seen in primary care, but other respiratory conditions, such as bronchiectasis, will also be seen. In this episode of the MIMS Learning Clinical Update podcast, MIMS Learning editors Dawn and Pat survey the wide range of respiratory conditions seen in primary care that are not COPD or asthma. They look at the diagnosis of bronchiectasis, improvements in managing cystic fibrosis, the rising incidence of tuberculosis (TB), and how the NHS Lung Cancer Screening Programme is enabling earlier diagnosis.Educational objectivesAfter listening to this podcast, healthcare professionals should be better able to: Describe the pathophysiology of bronchiectasisReview how developments in screening and management has improved outcomes in cystic fibrosisDiscuss which socioeconomic groups are at increased risk of tuberculosisRecall the number of lung cancers detected through the NHS lung cancer screening programmeYou can access the website version of this podcast, along with a list of key learning points, on MIMS Learning - and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.MIMS LearningSubscribe to MIMS LearningBronchiectasis: clinical reviewCystic fibrosis: clinical reviewInflammatory bowel disease mimicsLung cancer: presentation and referralPodcast: advanced nurse practitioner Beverley Bostock on asthma and COPDPodcast bonus episode: Dr Steve Holmes on asthma in pregnancy and childhood wheezeMIMSEarly start to flu season prompts warning for healthcare professionalsInfluenza vaccines 2025/2026Influenza vaccines, which vaccine to offer Hosted on Acast. See acast.com/privacy for more information.

Dr. Sumedha Sonde, pulmonologist and critical care physician at Hamilton Physician Group - Specialty Care in Dalton, Georgia. Dr. Sonde completed residency training in Anesthesia and Pain Management and additional residency training in Internal Medicine. She then completed a Pulmonary and Critical Care fellowship in New York.Dr. Sonde treats patients with sleep or pulmonary disorders. chronic obstructive pulmonary disease (also referred to as COPD), asthma, pulmonary fibrosis, lung cancer, COVID conditions, pneumonia, acute and chronic pulmonary hypersensitivity conditions, pulmonary hypertension, bronchiolitis, and more. For more information or an appointment at Hamilton Physician Group - Specialty Care, call 706-529-3072 or visit VitruvianHealth.com/specialtycare. This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Think vaping is safer than smoking? This Baptist HealthTalk episode will make you think twice.In this new conversation with pulmonologist Dr. Sosa, he breaks down what really happens when you vape and why the risks are much more serious than most people realize.You'll hear: • What's actually inside a vape and why it matters • How vaping affects lungs, especially in developing teens • The hidden chemicals and exposures most people never hear about • The truth behind “one pod equals one pack” • What parents need to know about the products kids can access today • Why flavors make addiction even easier • How fast habits form and why they're so hard to breakIf you or someone you love vapes, this is a conversation you don't want to miss.Host:Johanna GomezAward-Winning Host & JournalistGuest:Andres F. Sosa, M.D.General and Interventional PulmonologistBaptist Health Baptist Hospital

“We have made great progress in treating lung cancer, but we still have a long way to go,” said Triparna Sen, PhD, a James scientist who specializes in translational research to better understand and treat lung cancer. Listen as Sen explains the biology and differences between the two different types of lung cancer (non-small cell and the less common, but more aggressive small cell); the latest treatments, including immunotherapy; and how a better understanding of the biology of cancer cells has led to improved drugs (such as immunotherapy) and better outcomes for patients. She also described how cancer cells are able to adapt and transform their biology and actually become “a new form of cancer.” Once this happens, over the course of several months, the immunotherapy drugs “no longer recognize the tumor.”

RaeAnn Tucker from the Henry and Stark County Health Departments joined Wake Up Tri-Counties to discuss Lung Cancer Awareness Month, the Great Smokeout on November 20th, insurance navigators, Covid and flu vaccines, the A1C test special, the food drive blood test special, and food safety. Residents of Henry and Stark Counties are encouraged to join the Great American Smokeout on November 20th, aiming to take that important first step toward quitting smoking. Local health departments are highlighting the significant health benefits of becoming tobacco-free, especially as November marks both Lung Cancer and Diabetes Awareness Months. Area clinics are offering discounted hemoglobin A1C tests for diabetes monitoring and updated COVID-19 and flu vaccinations. As the holidays approach, officials also urge extra food safety precautions to prevent illness at gatherings. For health support, resources, and vaccination information, contact the local health department or First Choice Healthcare clinics.

Early detection saves lives. Learn how advanced screening programs and robotic technology are transforming the fight against lung cancer. In this episode, Dr. Peter Olivieri, III, a pulmonologist and critical care leader at UM Baltimore Washington Medical Center, explains who should be screened, how the process works, and what makes today's minimally invasive diagnostic tools so precise and effective.

Lung cancer is the third most common cancer in the U.S. It's caused by harmful cells in your lungs growing unchecked. Treatments include surgery, chemotherapy, immunotherapy, radiation and targeted drugs. Screening is recommended if you're at high risk. Advances in treatments have caused a significant decline in lung cancer deaths in recent years. ​ Lung cancer is a disease caused by uncontrolled cell division in your lungs. Your cells divide and make more copies of themselves as a part of their normal function. But sometimes, they get changes (mutations) that cause them to keep making more of themselves when they shouldn't. Damaged cells dividing uncontrollably create masses, or tumors, of tissue that eventually keep your organs from working properly. Lung cancer is the name for cancers that start in your lungs — usually in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that start in other places and move to your lungs are usually named for where they start (your healthcare provider may refer to this as cancer that's metastatic to your lungs). ​ There are many cancers that affect the lungs, but we usually use the term "lung cancer" for two main kinds: non-small cell lung cancer and small cell lung cancer.  Other types of cancer can start in or around your lungs, including lymphomas (cancer in your lymph nodes), sarcomas (cancer in your bones or soft tissue) and pleural mesothelioma (cancer in the lining of your lungs). These are treated differently and usually aren't referred to as lung cancer.  (CREDITS: Cleveland Clinic)

The UK Markey Cancer Center's upcoming Lung Cancer Forum scheduled for Dec. 11. Dr. Weisi Yan joined us to chat about it.  Learn more about Weisi Yan, MD, PhD  

Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey. Guests: Ting Bao, MD, MS, FSIO Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Member of the Faculty, Harvard Medical School Dana-Farber Cancer Institute Jun J. Mao, MD, MSCE Chief, Integrative Medicine Service Laurance S. Rockefeller Chair in Integrative Medicine Professor of Medicine, Weill Cornell Medicine Memorial Sloan Kettering Cancer Center Lisa Davis, PharmD, FCCP, BCPS, BCOP, Clinical Professor, Pharmacy Practice & Science The University of Arizona, R. Ken Coit College of Pharmacy

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:Benjamin Levy, MD, FASCOAssociate ProfessorJohns Hopkins School of MedicineClinical DirectorJohns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)Washington, DCAlex Spira, MD, PhD, FASCODirector Clinical ResearchVirginia Cancer SpecialistsCEO NEXT Oncology VirginiaFairfax, VirginiaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/4qZLR6B Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Only about one in six lung cancer cases nationwide are caught early enough for curative treatment. In Hampton Roads, health advocates say it's time to widen screening guidelines.

Lung cancer is the deadliest cancer in Ireland with an estimated 1900 deaths per annum and its the second most common cancer in Ireland for women. While many associate this type of cancer with smokers, one in five diagnosed people have never smoked in their lives. One of these people is Susan Leatham who was diagnosed in 2021 and Susan spoke to Pat this morning along with Helen Forristal, Director of Nursing with the Marie Keating Foundation.

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

A powerful hour on health and hope: addressing intimate partner violence in care settings, raising lung-cancer awareness with early screening, and expanding STEM education across ND.

US Veterans are at a heightened risk for lung cancer due to service-related exposures. Integrating clinical research into routine oncology care at the US Department of Veterans Affairs (VA) can help bring clinical trials closer to where Veterans live and improve access to cutting edge therapies. In this episode, CANCER BUZZ speaks with Millie Das, MD, chief of oncology at the VA Palo Alto Health Care System, about the collaborations and institutional support that allowed them to launch lung cancer clinical trials and the role industry has played.     "My primary motivation was just to allow veterans access to trials in the same way that I saw my patients at Stanford have access to clinical trials." - Millie Das, MD   "One of the biggest myths is that you can't work with pharma within the VA and I think just trying to break down some of these old myths was a challenge." - Millie Das, MD     Guest:                  Millie Das, MD Chief, Oncology VA Palo Alto Health Care System Clinical Professor Stanford University Stanford, CA     Additional Reading/Resources   ·      Veterans Care Resource Library ·      Improving Cancer Care for Native American Veterans: A Model of Interagency Collaboration

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Mark Socinski, MD, a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida. Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory, as well as the personal influences that helped him arrive where he is today. Socinski describes himself as a clinician and clinical investigator with 35 years of focus on lung cancer. His role as executive director of the AdventHealth Cancer Institute involves maintaining an active clinic 1 day a week and dedicating the rest of his time to administrative duties, including recruitment and building infrastructure at the institution. In the interview, Dr Socinski explained that he was influenced to enter a career in medicine because of role of the family practitioner he knew growing up. He went on to receive undergraduate and medical degrees from the University of Vermont in Burlington. After training at Dana-Farber Cancer Institute in Boston, Massachusetts, he began his career in private general oncology practice in Vermont before seeking a more academic, subspecialty environment. He joined the University of North Carolina to concentrate on lung cancer, where he pioneered dose-escalation trials using conformal radiotherapy. Dr Socinski then described his move to the University of Pittsburgh Medical Center in Pennsylvania. There, he became the chair of the lung pathway, which limits treatment options to a single, expert-agreed standard of care based on efficacy, toxicity, and cost, thus reducing treatment heterogeneity and controlling costs. Thereafter, Dr Socinski moved to AdventHealth, attracted by the institution's goal to achieve National Cancer Institute designation and build a major cancer program. Dr Socinski shared that he finds it gratifying to care for patients and lead the development of the institute.

Breaking down the impact and legacy of Nancy Pelosi following her retirement announcement. A new state law makes it easier for high school students to go to CSUs. Finally, analyzing the annual State of Lung Cancer report through a California lens.

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

Click here to view the full article on Oncology Data Advisor: https://oncdata.com/mary-pasquinelli-sybil-ai In this episode of Exploring AI in Oncology, Dr. Waqas Haque speaks with Mary Pasquinelli, DNP, Nurse Practitioner and Director of the Lung Screening Program at the University of Illinois (UI) Health, about the evolving role of screening and artificial intelligence (AI) in lung cancer detection. Their conversation spans program design, health equity, AI validation in diverse populations, multimodal detection with circulating tumor DNA (ctDNA) and imaging, and practical strategies that boost adherence and impact in both academic and community settings.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer. Episode Highlights: MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach. FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC. SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib. Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients. Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care.  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to subscribe for more updates on practice-changing research and major conference highlights! #ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

In this podcast, we review a comparison of outcomes in patients 65-74 years old from SEER-Medicare and NLST datasets in stage I lung cancer with study first author, Dr. Nichole Tanner as well as Dr. Neal Navani.

Drs. Cooper and Rotow review the challenges of CNS involvement in HER2+ NSCLC, emphasizing the importance of baseline and ongoing brain imaging, and the emerging understanding of CNS penetrance for HER2-targeted therapies. They explore strategies for managing brain metastases, including balancing local therapies, including radiation with systemic treatments, and highlight the need for multidisciplinary approaches and further research on CNS activity in clinical trials.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez speaks with two remarkable young lung cancer advocates Samantha Murell and Megan Flanagan, who are redefining what it means to live with the disease. They share their journeys from diagnosis to advocacy, shedding light on the challenges young patients face, breaking misconceptions, and offering hope to others along the way.

Drs. Rotow and Cooper explore the evolving landscape of HER2+ NSCLC treatment, highlighting recent advancements in targeted therapies like HER2 TKIs and antibody-drug conjugates. They emphasize the importance of comprehensive biomarker testing, the significance of personalized treatment approaches, and the exciting progress in providing more effective and tolerable second-line therapies for patients. The discussion underscores the field's movement toward precision medicine and the potential for future combination strategies and improved patient outcomes.

Drs. Cooper and Rotow discuss first-line treatment strategies for HER2+ NSCLC, highlighting the importance of comprehensive molecular testing and emerging targeted therapies. Key considerations include the efficacy of antibody-drug conjugates and TKIs, with ongoing clinical trials evaluating their potential as frontline treatments. The discussion emphasizes the need for personalized treatment approaches based on individual patient characteristics, molecular features, and the evolving landscape of HER2-targeted therapies.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Zsolt Megyesfalvi moderates a discussion in Hungarian about highlights from the conference with Dr. Zsuzsanna Keleman, Dr. Lilla Horvath, and Dr. Gyula Ostoros.

I recently had an ApoB test and am surprised that it isn't lower than it is.  Can you explain?I have an ascending thoracic aortic aneurysm.  How can I keep it from enlarging?Why are you against whole-body scans? Aren't they helpful?Can I take magnesium L-threonate while also taking magnesium glycinate?

Will Truheight vitamins really make your kids grow?Where can I learn more about complementary medicine and nutrition?The balls of my feet are sore along with my toes. Is this a vitamin deficiency?

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

In this episode of Thinking Thoracic, host Dr. Erin Gillaspie talks with Dr. Robert Lentz and Dr. Fabien Maldonado about the groundbreaking VERITAS trial, which is reshaping how clinicians diagnose lung cancer. Published in the New England Journal of Medicine, the VERITAS trial compared navigational bronchoscopy with CT-guided biopsy in a rigorous, randomized design, bringing much-needed evidence to interventional pulmonology. The discussion explores how the study was conceived, why robust device trials are vital to patient outcomes, and what the findings mean for the future of minimally invasive lung diagnostics.

A Colorado doctor was diagnosed with the same lung cancer he's researched and treated all his life. He only recently decided to share his story when chemotherapy made him horribly sick. Dr. Ross Camidge talks about sharing the same path as his patients, and how he views death and what comes next. Then, from artwork to hidden history on the walls, Purplish explores the many stories the state capitol has to tell. Plus, just in time for Halloween, a Colorado haunting... and a reimagining of Ichabod Crane. 

Riverside Healthcare Imaging Patient Navigator Maureen Elliott discusses what to expect from a CT lung cancer screening and who should schedule an appointment.

This episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas. Dr. Pedro Rocha from Vall d'Hebron University Hospital in Barcelona, Spain. Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JYH865. CME credit will be available until October 20, 2026.The Earlier the Better in Lung Cancer: Multispecialty Guidance on Screening, Diagnosis and Management of Resectable NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Early detection saves lives, but today's tools are often invasive, slow, or used too late. In this episode, Breath Diagnostics CEO Ivan Lo explains how a non-invasive breath test can detect volatile organic compounds (VOCs) associated with disease—positioning breath as a first-line screen for early-stage lung cancer and potentially pneumonia and TB. We cover the science (why breath can capture near real-time biological change), sensitivity/specificity signals from 800+ patients, and a go-to-market/regulatory plan that prioritizes post-op pneumonia (shorter trials, no entrenched standard of care) before lung cancer screening. We also discuss platform economics (low-cost disposables, existing LC-MS infrastructure), trial scale and cost, and how breath could support ongoing monitoring after treatment. Investors get a clear view of timelines, risks, and upside; founders get lessons on platform positioning, capital efficiency, and sequencing indications. Highlights include...Why breath (VOCs) can surface disease signals minutes–hours after biological changeFirst-line screening thesis vs. liquid biopsy and CT workflowsEarly data: ~94% sensitivity / 85% specificity across 800+ patients (lung cancer context)Regulatory path: post-op pneumonia first (faster FDA route), lung cancer nextUnit economics: low-cost cartridge + existing LC-MS labs (hub-and-spoke)Clinical design: trial scale, costs, and companion-diagnostic “cocktail” potentialPlatform beyond oncology: pneumonia, TB, inflammation, RUO for pharmaChapters00:00 Intro & why early detection needs a rethink00:47 What Breath Diagnostics does (the “breath bag”)03:34 VOCs 101: why breath can be earlier than blood06:41 First-line screen vs. confirmatory tests08:19 Will this be ubiquitous at annual visits?11:53 Commercialization path & funding realities12:37 Pneumonia first: faster FDA route14:09 Lung cancer timeline & business model15:34 Hospital economics & pneumonia savings18:24 Trial scale/costs; disposable chip economics20:34 Team, funding strategy, and sequencing22:08 Early data and a “false negative” biopsy case24:12 TAM & eligibility (20M Americans qualify)25:06 What success looks like (2–3 years)27:00 Investor closing thoughts

Lung cancer in nonsmoking individuals is increasing worldwide and currently accounts for 15% to 20% of lung cancer cases globally. Benjamin Solomon, PhD, of the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses the epidemiology and treatment of lung cancer in nonsmoking patients with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Lung Cancer in Nonsmoking Individuals ----------------------------------- JAMA Editors' Summary

Reasons for nausea  My PSA was 4.0 six months ago, and now it's up to 4.55. What should I do?I have lupus and need to take Methotrexate. How can I protect my liver and immune system?The important relationship between vitamin D3 and K2

How do I keep my LDL low enough without compromising my brain and my liver?I read that fish oil can raise LDL cholesterol. Is this true?A questionable case study on pycnogenol

Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.